Mandate

Vinge has advised Vicore Pharma Holding AB (publ) in connection with its rights issue

October 22, 2024 M&A

Vinge has advised Vicore Pharma Holding AB (publ) in connection with an oversubscribed rights issue of shares whereby Vicore receives issue proceeds of approximately SEK 782 million before deduction of transaction costs.

The new shares issued in the rights issue are expected to be admitted to trading on Nasdaq Stockholm on or around 22 October 2024. Vicore is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is advancing a portfolio of therapies in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's shares are listed on Nasdaq Stockholm.

Vinge’s team consisted primarily of Rikard Lindahl, Joel Magnusson, Annie Fällström and Carl Lexenberg.

Related

Vinge advises HAKI Safety AB in connection with the acquisition of Trimtec

Trimtec is a Swedish distributor of high-tech precision equipment.
February 14, 2025

Vinge advises Industrifonden in connection with its investment in Agteria Biotech

Vinge has advised Industrifonden in connection with their participation as lead investor, together with AgriZeroNZ, in the seed financing round in Agteria Biotech AB.
February 13, 2025

Vinge advises Axcel and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB

Vinge has advised Axcel VII and Accru Partners in connection with the acquisition of Sporrong & Eriksson Revisionsbyrå AB.
February 12, 2025